Agammaglobulinemia
MONDO:0015977A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.
Also known as: agammaglobulinemia, Gammaglobulin Deficiency, Immunoglobulin Deficiency, antibody Deficiency
85 clinical trials for this condition and its sub-types, 16 tagged with Agammaglobulinemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Agammaglobulinemia
-
Syndromic agammaglobulinemia 7 trials · 37 incl. sub-types
3 sub-types
- Common variable immunodeficiency 29 trials · 31 incl. sub-types Sub-types →
- Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome 0 trials
- Transient hypogammaglobulinemia 0 trials Sub-types →
-
Activated PI3K-delta syndrome 5 trials · 6 incl. sub-types
2 sub-types
- Immunodeficiency 14 6 trials
- Immunodeficiency 36 with lymphoproliferation 0 trials
-
Isolated agammaglobulinemia 0 trials · 4 incl. sub-types
2 sub-types
- Bruton-type agammaglobulinemia 4 trials
- Autosomal agammaglobulinemia 1 trial Sub-types →
-
Good syndrome 0 trials
-
Congenital agammaglobulinemia 0 trials
-
Immunodeficiency 61 0 trials
Most studied deeper sub-types
-
Rewriting the code: a One-Time gene fix for a rare immune disease?
Cure By invitation onlyThis trial tests a one-time gene therapy for WHIM syndrome, a rare inherited immune disorder that causes severe infections. Doctors collect a person's own blood stem cells, use base editing to correct the faulty CXCR4 gene, and return the edited cells to the body. The goal is to …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 21, 2026 16:00 UTC
-
New antibody therapy aims to shield kids with rare immune disease from deadly infections
Disease control OngoingThis study tests a medicine called Kedrion IVIG 10% in 30 children with primary immunodeficiency, a condition where the immune system doesn't work properly. The treatment is made from donated antibodies and is given through a vein to help prevent serious bacterial infections. Res…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC